Find your next paid study

D3 Bio (Wuxi) Co., LtdNCT05886920

Advanced Solid TumorsBreast Cancer RecurrentOvarian Cancer+4 more

A Phase 1/2, Open-Label, Dose-Escalation and Expansion First-In-Human Study of ATX-295, an Oral Inhibitor of the Kinesin Motor Protein KIF18A, as Monotherapy and in Combination With Anticancer Therapy in Patients With Locally Advanced or Metastatic Solid Tumors, Including High-Grade Serous Ovarian Cancer

The goal of this study is to identify a safe and tolerated dose of the orally administered KIF18A inhibitor ATX-295. In addition, this study will evaluate the …

Accent TherapeuticsNCT06799065

Phase 2

Phase II Protocol of Proton Therapy for Partial Breast Irradiation in Early Stage Breast Cancer

The purpose of this research study is to compare the effects (good and bad) on women and their cancer using proton radiation therapy. This study is being done…

Breast CancerBreast NeoplasmBreast Tumor+1 more

Proton Collaborative GroupNCT01766297

A Phase 1 / 2, Open-Label Study of REC-7735 in Participants With Unresectable, Locally Advanced, or Metastatic PIK3CA-H1047R Mutated Solid Tumors

The study is designed to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary anti-tumor activity of REC-7735 i…

Solid Tumors

Recursion Pharmaceuticals Inc.NCT07819136

Phase 2

A Phase 2/3, Multicenter, Randomized Open-Label Study of Zanzalintinib vs Everolimus in Participants With Previously Treated, Unresectable, Locally Advanced or Metastatic Neuroendocrine Tumors

The primary purpose of this study is to assess the effectiveness of zanzalintinib compared to everolimus in participants with previously treated, unresectable,…

Pancreatic Neuroendocrine Tumor (pNET)Extra-Pancreatic Neuroendocrine Tumor (epNET)

A Phase 1a/1b Open Label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Activity of DBC-664 in Adult Patients With Locally Advanced or Metastatic Solid Tumors

DBC-664-ONC-101 is a first-in-human Phase 1a/1b open-label, multicenter study to evaluate the safety, tolerability, PK, pharmacodynamic, and preliminary anti-t…

Malignant Germ Cell TumorLung AdenocarcinomaGastric/Esophageal/Gastroesophageal Junction (GEJ) Adenocarcinoma+3 more

Duboce Biopharmaceuticals, Inc.NCT07705035

Remote Digital Physiological Data Collection in Cancer: An MSK Registry Protocol

The purpose of this study is to develop a secure method of collecting physiologic information from patients with cancer. The researchers will use this informat…

Solid Tumor

Memorial Sloan Kettering Cancer CenterNCT05390827

~$10 – $750

Advanced Solid TumorMetastatic Solid Tumor

Phase 1/2, Open-label, Multicenter, First-in-Human Study of DS-3939a in Subjects With Advanced Solid Tumors

This study will evaluate the safety, tolerability, and efficacy of DS-3939a in participants with advanced solid tumors.

Daiichi SankyoNCT05875168

Solid TumorsAdvanced Solid Tumor

A Phase 1a/b Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BG-C0902, an Antibody-Drug Conjugate Targeting Epidermal Growth Factor Receptor (EGFR) × Mesenchymal-Epithelial Transition (MET), Alone and in Combination With Other Therapeutic Agents in Patients With Advanced Solid Tumors

This study is a first-in-human (FIH), Phase 1a/1b study of BG-C0902, a fully humanized anti-epidermal growth factor receptor (EGFR) and anti-mesenchymal-epithe…

BeOne MedicinesNCT07181681

A Phase 1/2 Trial Of Larotrectinib And Pembrolizumab In Patients With Solid Tumors Previously Treated With Immune Checkpoint Inhibitor Monotherapy

This is a single-center, open-label Phase 1/2 trial evaluating the safety and efficacy of the combination of larotrectinib and pembrolizumab in patients with a…

Solid Tumor

M.D. Anderson Cancer CenterNCT07843550

~$10 – $6,250

Recurrent GlioblastomaGlioblastoma IDH (Isocitrate Dehydrogenase) WildtypeRelapsed Cancer+12 more

Phase 1/Phase 2 Open Label Trial of a Novel Indenoisoquinolone C-MYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma

Background: Glioblastoma is a common brain cancer in adults. Treatment includes surgery, radiation, and chemotherapy. But this cancer can return after treatme…

National Institute of Neurological Disorders and Stroke (NINDS)NCT07416188

~$10 – $5,625

Phase 3

A Phase 3, Single-Arm, Open-label, Pivotal Study to Evaluate the Efficacy and Safety of Ersodetug Compared to Baseline in Patients With Inadequately Controlled Hypoglycemia Due to Tumor Hyperinsulinism (Tumor HI)

The objectives of this study are to evaluate the glycemic efficacy, safety, and tolerability of ersodetug as add-on to standard of care (SOC) therapy for treat…

Tumor Hyperinsulinism (Tumor HI)